Rockville, MD and Seoul, South Korea 9/13/11—Seegene has raised $16.6 million through an offering of 636,500 shares on the KOSDAQ, the Korean Stock Exchange. Seegene provides PCR technology for molecular diagnostics and research applications. “Our products are defining a new category of molecular diagnostics that are capable of simultaneously detecting multiple pathogens or genetic mutations in a single test,” said Seegene CEO Jong-Yoon Chun. The company generated 2009 revenues of $11.2 million and had sales of $9.5 million in the first half of this year. Seegene’s ACP (Annealing Control Primer), DPO (Dual Priming Oligonucleotide) and READ (Real Amplicon Detection) technologies improve the sensitivity and specificity of PCR and real time PCR, enabling multi-pathogen detection according to the company.